Lanarkshire-based biotech firm ILC Therapeutics has announced a research partnership with the University of St Andrews to work on a drug which could save the lives of Covid-19 patients.
Scientists at ILC believe Alfacyte could be more effective than other drugs in preventing Covid-19 induced acute respiratory distress syndrome (ARDS).
They say it could reduce the need for many patients to be on a ventilator and could limit both short and long-term damage to lungs.
ILC, based at Biocity in Newhouse, is working with Dr Catherine Adamson of St Andrews' School of Biology on progressing Alfacyte to clinical trials. The drug is based on a new type of interferon, a defence-triggering protein in which Adamson has expertise.
ILC Therapeutics founder and chief scientific officer Professor William Stimson, formerly of the University of Strathclyde, said: “We are delighted to be working with the University of St Andrews to develop our research and work as quickly as possible to bring this potential treatment option to those who need it.
"Dr Adamson’s work in the field of virology is highly respected, and to have her backing in our research for Alfacyte is invaluable as we progress towards eventual clinical trials.”
Dr Adamson added: “I welcome the opportunity to work with ILC Therapeutics to carry out further research into the part interferons play in the innate immune system’s ability to fight Covid-19. By exploring this in more detail, we can hopefully move closer to having viable treatment options in the coming years.”
